Therapeutic Asset Ratings
145 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Intismeran
Renal Cell Carcinoma
Merck Sharp & Dohme LLC
P2
CCC
(48)
Pd-L1 T-Hank
Renal Cell Carcinoma
ImmunityBio, Inc.
P2
CCC
(48)
Pucotenlimab
Renal Cell Carcinoma
Sun Yat-sen University
P2
CCC
(48)
ro7247669
Renal Cell Carcinoma
Hoffmann-La Roche
P2
CCC
(48)
VIPIVOTIDE TETRAXETAN
Renal Cell Carcinoma
Dana-Farber Cancer Institute
P2
CCC
(48)
Zirconium Zr 89 Crefmirlimab Berdoxam
Renal Cell Carcinoma
ImaginAb, Inc.
P2
CCC
(48)
Pyrotinib
Renal Cell Carcinoma
HiFiBiO Therapeutics
P1/2
CC
(46)
rc48-adc
Renal Cell Carcinoma
HiFiBiO Therapeutics
P1/2
CC
(46)
n-803
Renal Cell Carcinoma
ImmunityBio, Inc.
P2
CC
(42)
Anti-Cd70-Car-T Cells
Renal Cell Carcinoma
Shanghai Changzheng Hospital
P1
CC
(42)
cd70-targeting car-t cells
Renal Cell Carcinoma
Chongqing Precision Biotech Co., Ltd
P1
CC
(42)
a2b395
Renal Cell Carcinoma
A2 Biotherapeutics Inc.
P1/2
CC
(41)
Alintegimod
Renal Cell Carcinoma
7 Hills Pharma, LLC
P1/2
CC
(41)
azd6750
Renal Cell Carcinoma
AstraZeneca
P1/2
CC
(41)
Bgb-A445
Renal Cell Carcinoma
BeiGene
P1/2
CC
(41)
FULVESTRANT
Renal Cell Carcinoma
Rain Oncology Inc
P1/2
CC
(41)
gen1160
Renal Cell Carcinoma
Genmab
P1/2
CC
(41)
gm103
Renal Cell Carcinoma
GeneMedicine Co., Ltd.
P1/2
CC
(41)
her2bbζ/cd19t+ t cells
Renal Cell Carcinoma
Shanghai Public Health Clinical Center
P1/2
CC
(41)
Inbrx-106
Renal Cell Carcinoma
Inhibrx Biosciences, Inc
P1/2
CC
(41)
Interleukin 18 (recombinant human mutein clone ST-067)
Renal Cell Carcinoma
Simcha IL-18, Inc.
P1/2
CC
(41)
neo212
Renal Cell Carcinoma
Neonc Technologies, Inc.
P1/2
CC
(41)
ngm707
Renal Cell Carcinoma
NGM Biopharmaceuticals, Inc
P1/2
CC
(41)
PEXMETINIB
Renal Cell Carcinoma
Dan Zandberg
P1/2
CC
(41)
Regorafenib
Renal Cell Carcinoma
Neonc Technologies, Inc.
P1/2
CC
(41)
Showing 51 to 75 of 145 assets
Previous
Page 3 of 6
Next